The country’s leading pharma company Aurobindo Pharma released the results of the first quarter of the financial year 2024-25 on Saturday, August 10. Aurobindo Pharma told the stock market exchanges that its net profit in the first quarter (April-June 2024) grew 61.20 per cent year-on-year to Rs 918.2 crore. The Hyderabad-based drug manufacturer had recorded a net profit of Rs 569.7 crore in the first quarter of the last financial year 2023-24.
Aurobindo Pharma’s revenue jumps 10.5 percent
The pharmaceutical company said in an exchange filing that in the first quarter of the current financial year, Aurobindo Pharma’s revenue has also increased well and it has jumped by 10.5 percent to Rs 7,567 crore. Whereas in the same period a year ago, their revenue was Rs 6,850.5 crore. Apart from this, a big increase has also been registered in the EBITDA of the company.
The company’s EBITDA increased by 40.7 percent to Rs 1619.5 crore
The company’s EBITDA grew by 40.7 percent to Rs 1619.5 crore in the first quarter of the current financial year from Rs 1151.3 crore in the first quarter of the previous financial year. The EBITDA margin of the pharma company also increased by 460 bps from 16.8 percent to 21.4 percent during this quarter.
The company’s vice chairman looked very happy with the financial results
K Nityananda Reddy, Vice Chairman and Managing Director, Aurobindo Pharma, said, “We are pleased with our continued strong performance this quarter, with strong revenue growth across all our business sectors.”
There was a big drop in the share price on Friday
Let us tell you that on Friday, there was a big decline in the shares of Aurobindo Pharma. The shares of the pharmaceutical company closed at Rs 1447.15 with a decline of Rs 32.20 (2.18%). However, the company’s shares are still trading around their 52 Week High. The 52 Week High of the company’s shares is Rs 1,497.65. According to BSE, the current market cap of the company is Rs 84,794.11 crore.
Latest Business News
